patients with chronic ITP who do not respond to or cannot tolerate TPO-RA drugs are treated with rituximab or mycophenolate. While there is no direct comparison between Tavlesse and these agents ...
The addition of brentuximab vedotin to lenalidomide and rituximab improved survival ... in each treatment arm developed neutropenia, thrombocytopenia, diarrhea or anemia. Researchers acknowledged ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback